These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38182946)

  • 1. Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example.
    Liang X; Koleske ML; Yang J; Lai Y
    AAPS J; 2024 Jan; 26(1):13. PubMed ID: 38182946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via Physiologically Based Pharmacokinetic Modeling.
    Bowman CM; Chen B; Cheong J; Liu L; Chen Y; Mao J
    Drug Metab Dispos; 2021 Jul; 49(7):530-539. PubMed ID: 33958385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys.
    Takahashi T; Ohtsuka T; Yoshikawa T; Tatekawa I; Uno Y; Utoh M; Yamazaki H; Kume T
    Drug Metab Dispos; 2013 Oct; 41(10):1875-82. PubMed ID: 23929936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance.
    Liang X; Lai Y
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):869-886. PubMed ID: 33793347
    [No Abstract]   [Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
    Duan P; Zhao P; Zhang L
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
    Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
    Cho CK; Mo JY; Ko E; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
    Arch Pharm Res; 2024 Feb; 47(2):95-110. PubMed ID: 38159179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
    Mochizuki T; Aoki Y; Yoshikado T; Yoshida K; Lai Y; Hirabayashi H; Yamaura Y; Rockich K; Taskar K; Takashima T; Chu X; Zamek-Gliszczynski MJ; Mao J; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Transl Sci; 2022 Jun; 15(6):1519-1531. PubMed ID: 35421902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes.
    Farasyn T; Pahwa S; Xu C; Yue W
    Eur J Pharm Sci; 2021 Oct; 165():105951. PubMed ID: 34311070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches.
    Izumi S; Nozaki Y; Komori T; Takenaka O; Maeda K; Kusuhara H; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2678-2687. PubMed ID: 28238896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
    Mitra P; Weinheimer S; Michalewicz M; Taub ME
    Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
    Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
    Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation.
    Liang X; Park Y; DeForest N; Hao J; Zhao X; Niu C; Wang K; Smith B; Lai Y
    Drug Metab Dispos; 2020 Dec; 48(12):1283-1292. PubMed ID: 33037043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.
    Matsunaga N; Ufuk A; Morse BL; Bedwell DW; Bao J; Mohutsky MA; Hillgren KM; Hall SD; Houston JB; Galetin A
    Drug Metab Dispos; 2019 Mar; 47(3):215-226. PubMed ID: 30593544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B.
    Park JE; Shitara Y; Lee W; Morita S; Sahi J; Toshimoto K; Sugiyama Y
    J Pharm Sci; 2021 Jan; 110(1):517-528. PubMed ID: 33058894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
    Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
    J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
    Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research.
    Li N; Badrinarayanan A; Ishida K; Li X; Roberts J; Wang S; Hayashi M; Gupta A
    AAPS J; 2020 Nov; 23(1):1. PubMed ID: 33196949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
    Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.